Atul Pranay

Associate Staff Scientist

Oklahoma Medical Research Foundation
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (15)

Year:

2026

Year:

2025

Background: Ovarian cancer is the deadliest of all gynecologic malignancies due to limited therapeutic options. Our data show that the tumor-specific metabolism of ovarian cancer could be effectively targetable, which highlights a path for new anti-cancer therapies. Methods and Results: Our work shows that the upregulation of mitochondrial enzyme SDHA is particularly prevalent in ovarian carcinoma. SDHA overexpression significantly induced orthotopic ovarian tumor growth, reducing mouse survival. We showed that SDHA-overexpressing tumors depend on glutaminolysis and increased activity of the tricarboxylic acid (TCA) cycle coupled with mitochondrial oxidative phosphorylation (OXPHOS), which are essential for high-energy metabolism and cell survival. We identified a distinctive vulnerability of SDHA-overexpressing tumors to agents targeting regulators of the OXPHOS pathway, particularly the LRPPRC protein. LRPPRC is a key regulator of mitochondrial energy metabolism, promoting OXPHOS and ATP generation. However, when overexpressed, the LRPPRC acts as a tumor oncogene. Our analysis of SDHA and LRPPRC gene and protein expression patterns in precursor lesions and established ovarian cancer demonstrated that the upregulation of SDHA is accompanied by LRPPRC overexpression, notably in advanced tumors. Our novel findings highlight for the first time a potential functional interaction between SDHA and LRPPRC in the development and progression of ovarian malignancy. Importantly, our in vivo data showed that pharmacological inhibition of LRPPRC results in a lasting therapeutic benefit and can be an effective therapy in SDHA- and LRPPRC-overexpressing ovarian tumors. Conclusions: Overall, our study underlines an understudied role of concomitant overexpression of SDHA and LRPPRC in ovarian cancer pathogenesis, highlighting new paths for therapeutic development.

Year:

2025

The 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase (PFKFB) family of proteins are bifunctional enzymes that are of clinical relevance because of their roles in regulating glycolysis in insulin sensitive tissues and cancer. Here, we sought to express recombinant PFKFB2 and develop a robust protocol to measure its kinase activity. These studies resulted in the unexpected finding that bacterially expressed PFKFB2 is phosphorylated in situ on Ser483 but is not a result of autophosphorylation. Recombinant PFKFB2 was used to develop an enzymatic assay to test a library of molecules selected by the Atomwise AtomNet® AI platform. This resulted in the identification of a new inhibitor, B2, that inhibits PFKFB2 (IC 50 3.29 μM) and PFKFB3 (IC 50 11.89 μM). A-498 cells, which express both PFKFB2 and PFKFB3, were treated with B2. Seahorse XFe analysis revealed B2 inhibited cellular glycolysis and glycolytic capacity. Targeted LC/MS analysis showed B2 decreased fructose-1,6-bisphosphate and downstream glycolytic intermediates but increased fructose-6-phosphate levels, which is consistent with an inhibitory effect on PFK-1 activity. The LC/MS metabolic profile of A-498 cells treated under identical conditions with the known PFKFB3 inhibitor, PFK158, was distinct from that induced by B2. These results thus demonstrate the identification and validation of a new PFKFB kinase inhibitor.

Year:

2025

The mitochondrial Ca 2+ uniporter (MCU) links energy metabolism to cell excitability and signalling throughout the lifespan. However, whether neural metabolism responds to MCU impairments in a sex‐specific manner has remained unknown, especially in models with partial MCU downregulation. Using hippocampal slices from adult heterozygous Mcu knock‐out (hKO) mice, we observed sexually dimorphic changes in NAD(P)H autofluorescence dynamics following neuronal stimulation. In male mice, these signals were preserved despite decreased mitochondrial Ca 2+ uptake, likely due to increased MDH2 levels and potentially other enzymes from the tricarboxylic acid cycle, the malate aspartate shuttle, and glycolysis. In contrast to males, neural tissue from female hKO mice showed delayed NAD(P)H production and limited NAD + availability when compared to sex‐matched controls, despite intact mitochondrial Ca 2+ uptake. In addition, both male and female hKO mice exhibit decreased NADP + levels and GSH/GSSG ratios (along with increased protein S ‐glutathionylation), indicating a weakened antioxidant capacity. Strikingly, markers of oxidative damage were also decreased (albeit more prominently in male mice), suggesting attenuated generation of reactive oxygen species. In addition, sex‐specific changes in the hippocampal metabolome were manifested in hKO mice, along with a common decrease in spermidine levels. However, spermidine‐dependent hypusination of eIF5A remained unaltered, suggesting further compensatory mechanisms at this age. In summary, our findings indicate that brain tissue can adapt to partial MCU deficits by salvaging most mitochondrial NADH production in active states, while compromising redox signalling and the polyamine pathway. The interplay between these molecular phenotypes likely impacts neurological conditions and potentially cognitive impairment with age. image Key points The inactivation of one Mcu allele (which encodes the mitochondrial Ca 2+ uniporter) leads to altered neuronal excitability and attenuated mitochondrial Ca 2+ elevations in active neurons from 6‐ to 12‐months‐old female and male mice, respectively. Tissue autofluorescence imaging reveals delayed mitochondrial NAD(P)H production in stimulated hippocampal tissue from female but not male heterozygous Mcu knockout mice. Mitochondrial Ca 2+ uniporter haploinsufficiency is characterized by a sex‐specific decrease in oxidative stress markers in the brain, despite a decline in NADP + levels and the GSH/GSSG ratio in both male and female mice. Changes in the abundance of enzymes and polar metabolites in brain tissue reveal sexually dimorphic metabolic remodelling in the context of Mcu haploinsufficiency. Life‐long downregulation of the mitochondrial Ca 2+ uniporter results in decreased hippocampal spermidine levels in adult male and female mice.

Year:

2025

Year:

2025

Background The heart’s constant energy demands make metabolic flexibility critical to its function as nutrient availability varies. The enzyme phosphofructokinase‐2/fructose 2,6‐bisphosphatase (PFKFB2) contributes to this flexibility by acting as a positive or negative regulator of cardiac glycolysis. We have previously shown that PFKFB2 is degraded in the diabetic heart and that a cardiac‐specific PFKFB2 knockout (cKO) impacts ancillary glucose pathways and mitochondrial substrate preference. Therefore, defining PFKFB2’s role in mitochondrial metabolic flexibility is paramount to understanding both metabolic homeostasis and metabolic syndromes. Further, it is unknown how PFKFB2 loss impacts the heart’s response to acute stress. Here, we examined how cardiac mitochondrial flexibility and the posttranslational modification O‐GlcNAcylation are affected in cKO mice in response to fasting or pharmacologic stimulation. Methods cKO and litter‐matched controls were euthanized in the fed or fasted (12 hours) states, with or without a 20‐minute stimulant stress of caffeine and epinephrine. Mitochondrial respiration, metabolomics, and changes to systemic glucose homeostasis were evaluated. Results cKO mice had moderate impairment in mitochondrial metabolic flexibility, affecting downstream glucose oxidation, respiration, and carnitine palmitoyl transferase 1 activity. O‐GlcNAcylation, a product of ancillary glucose metabolism, was upregulated in cKO hearts in the fed state, but this was ameliorated in the fasted state. Furthermore, metabolic remodeling in response to PFKFB2 loss was sufficient to impact circulating glucose in fasted and stressed states. Conclusions PFKFB2 is essential for fed‐to‐fasted changes in cardiac metabolism and plays an important regulatory role in protein O‐GlcNAcylation. Its loss also affects systemic glucose homeostasis under stressed conditions.

Year:

2025

Cardiac aging is associated with metabolic changes, including an increased reliance on glycolysis, and an increased susceptibility to cardiovascular diseases. This study explores the relationship between enhanced cardiac glycolysis and aging using the Glyco Hi mouse model, characterized by constitutively elevated glycolysis. We compared cardiac function, metabolism, mitochondrial performance, and hallmarks of aging between aged (21 and 24 months) Glyco Hi and wild-type (WT) mice across sexes. Our findings reveal modest reductions in cardiac function in aged Glyco Hi mice compared to WT mice, with sex-specific differences in heart size and collagen concentration. Female Glyco Hi hearts exhibited hypertrophy without fibrosis, while males showed elevated collagen levels. Whole-body metabolic assessments revealed similar energy expenditure and respiratory patterns across genotypes, with females displaying less circadian-associated variation in metabolism. Mitochondrial analyses showed that aged Glyco Hi hearts maintained metabolic adaptations favoring glycolysis but did not exhibit significant bioenergetic dysfunction or oxidative stress. Pyruvate dehydrogenase activity, initially elevated in younger Glyco Hi hearts, normalized to WT levels with age. Proteomic and metabolomic analyses highlighted distinct profiles between genotypes, with Glyco Hi hearts exhibiting increased glycolytic enzyme levels and reduced abundance of fatty acid oxidation proteins. Despite these differences, indicators of oxidative stress, proteostasis, and cellular senescence were comparable between genotypes, suggesting no acceleration of aging-related dysfunction. This study demonstrates that increased cardiac glycolysis alone does not suffice to drive accelerated cardiac aging. Instead, metabolic and functional changes in aged Glyco Hi hearts reflect adaptations rather than pathological declines, providing insights into potential metabolic targets for interventions against cardiac aging.

Year:

2025

Background The heart’s constant energy demands make metabolic flexibility critical to its function as nutrient availability varies. The enzyme phosphofructokinase-2/fructose 2,6-bisphosphatase (PFKFB2) contributes to this flexibility by acting as a positive or negative regulator of cardiac glycolysis. We have previously shown that PFKFB2 is degraded in the diabetic heart and that a cardiac-specific PFKFB2 knockout (cKO) impacts ancillary glucose pathways and mitochondrial substrate preference. Therefore, defining PFKFB2’s role in mitochondrial metabolic flexibility is paramount to understanding both metabolic homeostasis and metabolic syndromes. Further, it is unknown how PFKFB2 loss impacts the heart’s response to acute stress. Here we examined how cardiac mitochondrial flexibility and the post-translational modification O-GlcNAcylation are affected in cKO mice in response to fasting or pharmacologic stimulation. Methods cKO and litter-matched controls (CON) were sacrificed in the fed or fasted (12 hours) states, with or without a 20 minute stimulant stress of caffeine and epinephrine. Mitochondrial respiration, metabolomics, and changes to systemic glucose homeostasis were evaluated. Results cKO mice had moderate impairment in mitochondrial metabolic flexibility, affecting downstream glucose oxidation, respiration, and CPT1 activity. O-GlcNAcylation, a product of ancillary glucose metabolism, was upregulated in cKO hearts in the fed state, but this was ameliorated in the fasted state. Furthermore, metabolic remodeling in response to PFKFB2 loss was sufficient to impact circulating glucose in fasted and stressed states. Conclusions PFKFB2 is essential for fed-to-fasted changes in cardiac metabolism and plays an important regulatory role in protein O-GlcNAcylation. Its loss also affects systemic glucose homeostasis under stressed conditions. Graphic Abstract Research Perspective This study raises and answers three key questions: how PFKFB2 contributes to cardiac mitochondrial metabolic flexibility, how post-prandial status regulates O-GlcNAcylation in a PFKFB2-dependent manner, and how altered cardiac glucose use impacts systemic glucose homeostasis under stress. These findings highlight a novel role for nutrient state in regulating cardiac metabolism, and especially O-GlcNAcylation, with PFKFB2 loss. Future studies should investigate whether reducing O-GlcNAcylation through fasting is sufficient to ameliorate pathological changes observed in the absence of PFKFB2.

Year:

2025

Background Phosphofructo‐2‐kinase/fructose‐2,6‐bisphosphatase (PFK‐2) is a critical glycolytic regulator responsible for upregulation of glycolysis in response to insulin and adrenergic signaling. PFKFB2, the cardiac isoform of PFK‐2, is degraded in the heart in the absence of insulin signaling, contributing to diabetes‐induced cardiac metabolic inflexibility. However, previous studies have not examined how the loss of PFKFB2 affects global cardiac metabolism and function. Methods and Results To address this, we have generated a mouse model with a cardiomyocyte‐specific knockout of PFKFB2 (cKO). Using 9‐month‐old cKO and control mice, we characterized the impacts of PFKFB2 on cardiac metabolism, function, and electrophysiology. cKO mice have a shortened life span of 9 months. Metabolically, cKO mice are characterized by increased glycolytic enzyme abundance and pyruvate dehydrogenase activity, as well as decreased mitochondrial abundance and beta oxidation, suggesting a shift toward glucose metabolism. This was supported by a decrease in the ratio of palmitoyl carnitine to pyruvate‐dependent mitochondrial respiration in cKO relative to control animals. Metabolomic, proteomic, and Western blot data support the activation of ancillary glucose metabolism, including pentose phosphate and hexosamine biosynthesis pathways. Physiologically, cKO animals exhibited impaired systolic function and left ventricular dilation, represented by reduced fractional shortening and increased left ventricular internal diameter, respectively. This was accompanied by electrophysiological alterations including increased QT interval and other metrics of delayed ventricular conduction. Conclusions Loss of PFKFB2 results in metabolic remodeling marked by cardiac ancillary pathway activation. This could delineate an underpinning of pathologic changes to mechanical and electrical function in the heart.

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Collaborators (12)

Venkateswararao Eeda

Assistant Professor

University of Oklahoma Health Sciences Center

UNITED STATES
View details

Pankaj Singh

Professor and Chair

University of Oklahoma Health Sciences Center

UNITED STATES
View details

Maria Fernanda Mendez Garcia

Assistant Professor of Research

University of Oklahoma Health Sciences Center

UNITED STATES
View details

Valerie B O’Donnell

Prof of Biochemistry

Cardiff University

UNITED KINGDOM
View details

Vibhudutta Awasthi

University of Oklahoma Health Sciences Center

UNITED STATES
View details

Jacob Brown

Florida State University

UNITED STATES
View details

Arik Davidyan

Assistant Professor

California State University Sacramento

UNITED STATES
View details

Aykhan Yusifov

Assistant Professor

Niagara University

UNITED STATES
View details

Pengchun Yu

Associate Professor

Oklahoma Medical Research Foundation

UNITED STATES
View details

Kenneth Humphries

Professor

Oklahoma Medical Research Foundation

UNITED STATES
View details

Benjamin Miller

Program Chair

Oklahoma Medical Research Foundation

UNITED STATES
View details

Tracy G. Anthony

Professor

Rutgers University

UNITED STATES
View details